Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
Global Pharmatech Inc
GBLPGlobal Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation. It also manufactures and sells other proprietary drugs, generics, and dietary supplements used to treat symptoms ranging from headaches, coughing, and dry mouth to infections, and numbness of limbs. The company markets its products through distributors, such as wholesale companies and chain store representatives, as well as through its sales force. Global Pharmatech, Inc. was founded in 2001 and is based in Changchun, China. Address: 509 Maoxiang Street, Changchun, China, 130 012
Analytics
WallStreetin tavoitehinta
–P/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut GBLP
Osinkoanalytiikka GBLP
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria GBLP
Osakkeen arvostus GBLP
Talousasiat GBLP
Tuloksia | 2019 | Dynamiikka |